Skip to main content
. 2017 Mar 21;8(22):35946–35961. doi: 10.18632/oncotarget.16412

Figure 5. Reparixin reduces TC SCs functional activities.

Figure 5

(A) The sphere-forming efficiency of Reparixin (30 μM)-treated 8505c, CAL62 and SW1736 cells, in the presence or absence of exogenous IL-8 (100 ng/ml), evaluated as average sphere number and diameter. *p < 0.05 compared to untreated cells (NT); §p < 0.05 compared to IL-8 treated cells. (B) Effect of Reparixin (30 μM) on self-renewal of CAL62 and SW1736 spheroids. Average number of formed spheres was shown. Generations were indicated as Fn. *p < 0.05 compared to untreated thyrospheres (NT). (C) Effect of Reparixin (30 μM) on the clonogenic potential of 8505c pBABE or IL-8 overexpressing spheroids. *P < 0.05 compared to 8505c pBABE; §p < 0.05 compared to the relative not-treated (NT) spheroids.